期刊文献+

阿茨海默氏病与肿瘤坏死因子水平及肿瘤坏死因子TNF-α-308G/A基因多态性的关系 被引量:2

Study on the Plasma TNF Level and TNF-α-308G/Apolymorphism in Patients with Alzheimer's Disease
下载PDF
导出
摘要 目的探讨肿瘤坏死因子A-308基因多态性与阿茨海默氏病的关系。方法用放免法测定TNF水平,运用多聚酶链反应技术检测66例阿茨海默氏病及143例正常人肿瘤坏死因子A-308基因多态性。结果AD组肿瘤坏死因子A-308TNF-α1/1、TNF-α1/2、TNF-α2/2表型频率分别为0.8636、0.1212、0.0152,对照组分别为0.8881、0.1049、0.070;AD组TNF-α1、TNF-α2基因频率分别为0.9242、0.0758;对照组分别为0.9021、0.0979,肿瘤坏死因子A-308各种基因型频率在患者组与正常对照组之间的差异无显著性(P>005),而血浆中TNF水平,阿茨海默氏病组明显高于对照组,两组之间比较差异有统计学意义(P<0.05)。结论血清TNF水平显著升高,提示炎性反应在Alzheimer病程中有重要作用,肿瘤坏死因子A-308基因多态性与AD无明显相关。 Objective To investigate the relationship between Alzheimer's disease and the plasma level of tumor necrosis factor (TNF) and TNF-α-308G/A gene polymorphism. Method Plasma level of TNF was measured by RIA,and the polymorphism of TNF-α-308G/A gene was screened by PCR-RELP. Result The frequencies of TNF-α-308G/A genotypes in AD group were 0.8636, 0.1212, and 0.0152 for the TNF-α1/1,TNF-α1/2,and TNF-α2/2, respectively. The allele frequencies of TNF-α and TNF-α2 were 0.9242 and 0.0758, respectively. The TNF-α1/1 ,TNF-α1/2, and TNF-α2/2 genotype frequencies of the control group were 0.8881 ,0.1049,and 0.070, respectively. The allele frequencies of TNF-α1 and TNF-α2 were 0.9021, and 0.0979, respectively. There were no significant differences in the genotype frequencies of TNF-α-308G/A gene between the patients and control group (P〉 0. 05). The plasma level of TNF of Alzheimer's disease group was significantly higher than that of control group (P〈 0.05). Conclusion Plasma TNF level is increased in Alzheimer's disease patients and may play an important role in the process of AD. However, no association was found between TNF-α-308G/A gene polymorphism and Alzheimer's disease.
出处 《热带医学杂志》 CAS 2007年第2期133-135,150,共4页 Journal of Tropical Medicine
关键词 阿茨海默氏病 肿瘤坏死因子 多态性 Alzheimer's disease TNF-α-308G/A gene polymorphism
  • 相关文献

参考文献13

二级参考文献54

  • 1南晓红,钟良军,阿达来提.肿瘤坏死因子A-308基因型与新疆伊犁地区哈萨克族重度慢性牙周炎的关系[J].实用口腔医学杂志,2004,20(5):636-638. 被引量:5
  • 2Bergamaschini L,Canziani S,Bottasso B,et al.Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner[J].Clin Exp Immunol,1999,115(3):526-533.
  • 3Mrak RE,Griffin WS.Interleukin-1,neuroinflammation,and Alzheimer's disease[J].Neurobiol Aging,2001,22(6):903-908.
  • 4Terreni L,De Simoni MG.Role of the brain in interleukin-6 modulation[J].Neuroimmunomodulation,1998,5(3-4):214-219.
  • 5Solomon Beka,Frenker Dan.Vaccination for the prevention and treatment of Alzheimer's disease[J].Drugs Today,2000,36(9):655-663.
  • 6DeWitt DA,Perry G,Cohen M,et al.Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease[J].Exp Neurol,1998,149(2):329-340.
  • 7Rogers J,Lue LF.Microglial chemotaxis,activation,and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease[J].Neurochem Int,2001,39(5-6):333-340.
  • 8Kalaria RN.Microglia and Alzheimer's disease[J].Curr Opin Hematol,1999,6(1):15-24.
  • 9Saas P,Boucraut J,Quiquerez AL,et al.CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation?[J].J Immunol,1999,162(4):2326-2333.
  • 10Strohmeyer R,Shen Y,Rogers J.Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain[J].Hum Mol Genet,2000,9(15):2281-2279.

共引文献29

同被引文献21

  • 1Ray B,Lahiri DK.Neuroinflammation in Alzheimer's disease:different molecular targets and potential therapeutic agents including curcumin.Curr Opin Pharmacol,2009,9:434-444.
  • 2Ajit D,Udan ML,Paranjape G,et al.Amyloid-beta (1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line.Biochemistry,2009,9:9011-9021.
  • 3Ruan L,Kang Z,Pei G,et al.Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease.Curr Alzheimer Res,2009,6:531-540.
  • 4American Psychiatric Association.Diagnostic and statistical manual of mental disorders.4th edition.Text revision.Washington,DC:American Psychiatric Press,2000.4:147-154.
  • 5Dubois B,Feldman HH,Jacova C,et al.Research criteria for the diagnosis of Alzheimer's disease:revising the NINCDS-ADRDA criteria.Lancet Neuro,2007,6:734-746.
  • 6Shaftel SS,Kyrkanides S,Olschowka JA,et al.Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology.J Clin Invest,2007,117:1595-1604.
  • 7Vural P,Degirmencioglu S,Parlldar-Karpuzoglu H,et al.The combinations of TNFalpha-308 and IL-6 -174 or IL-10 -1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer's disease.Acta Neurol Scand,2009,120:396-401.
  • 8Tobinick E.Tumour necrosis factor modulation for treatment of Alzheimer's disease:rationale and current evidence.CNS Drugs,2009,23:713-725.
  • 9Weisman D,Hakimian E,Ho GJ,et,al.Interleukins,inflammation and mechanisms of Alzheimer's disease.Vitam Horm,2006,74:505-530.
  • 10ADAPT Research Group,Meinert CL,McCaffrey LD,et al.Alzheimer' s disease anti-inflammatory prevention trial:design,methods,and baseline results.Alzheimers Dement,2009,5:93-104.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部